A Phase II Basket Trial of Glutaminase Inhibitor (BeGIN) CB-839 HCl in Patients with NF1 Aberrations NF1 Mutant Malignant Peripheral Nerve Sheath Tumors (MPNST) KEAP1/NRF2 and LKB1 Aberrant Tumors

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Nf1 Aberrations, Nf1 Mutant Malignant Peripheral Nerve Sheath Tumors (mpnst), Keap1/nrf2 And Lkb1 Aberrant Tumors
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Patients must have histologically confirmed malignancy that is metastatic or unresectable. 3.1.2 Patient must have histopathologic confirmation of advanced solid tumor with NF1 mutation, NF1 mutant MPNST, KEAP1/NRF2 mutant and STK11/LKB1 mutant tumors by genetic sequencing. 2) Patient must have exhausted all available standard therapies .

You may not be eligible for this study if the following are true:

  • 1) Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study. 2) Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > Grade 1). 3) Patients who are receiving any other investigational agents.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.